Table 1:
Baseline characteristics of the cohort according to actual treatment with endovascular therapy
| PRove-IT Late-Window Cohort (n = 86) |
||||||
|---|---|---|---|---|---|---|
| Favorable mCTA Profile (n = 63) |
Favorable DEFUSE Profile (n = 58) |
Favorable DAWN Profile (n = 32) |
||||
| EVT | No EVT | EVT | No EVT | EVT | No EVT | |
| No. | 33 (52.4%) | 30 (47.6%) | 28 (48.3%) | 30 (51.7%) | 18 (56.3%) | 14 (43.7%) |
| Agea | 75 | 72 | 75 | 72 | 75 | 77 |
| NIHSS scorea | 18 | 12 | 18 | 14 | 19 | 18 |
| ASPECTSa | 9 | 9 | 9 | 8 | 9 | 9 |
| Onset/LSN to imaging (min)a | 578 (9.6 hr) | 580 (9.7 hr) | 559 (9.3 hr) | 571 (9.5 hr) | 608 (10.1 hr) | 593 (9.9 hr) |
| Occlusion site | ||||||
| Terminal ICA | 12 (36.4%) | 3 (10%) | 10 (35.7%) | 4 (13.3%) | 7 (38.9%) | 3 (21.4%) |
| M1 | 14 (42.4%) | 13 (43.3%) | 10 (35.7%) | 13 (43.3%) | 6 (33.3%) | 5 (35.7%) |
| M2 | 6 (18.2%) | 14 (46.7%) | 7 (25%) | 13 (43.3%) | 4 (22.2%) | 6 (42.9%) |
| M3 or distal | 1 (3%) | 0 | 1 (3.6%) | 0 | 1 (5.6%) | 0 |
Note:—LSN indicates last seen normal.
a
Denotes median.